Insmed reported $78.08M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Cytokinetics 66.77M 165.03M Jun/2025
DBV Technologies -30442000 30.56M Sep/2024
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Insmed USD 78.08M 6.53M Jun/2025
Novartis USD 11.52B 1.27B Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025